RPRX Royalty Pharma plc - Class A

  1. Stocks
  2. Healthcare
  3. NASDAQ: RPRX

Price (delayed)

$61.31

Market cap

$35.25B

P/E Ratio

32.61

Dividend/share

$0.93

EPS

$1.88

Enterprise value

$43.4B

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 77
Highlights
The company's quick ratio has surged by 121% YoY and by 6% QoQ
The revenue has increased by 10% YoY and by 3.9% from the previous quarter
The P/E is 35% higher than the last 4 quarters average of 24.1 but 28% lower than the 5-year quarterly average of 45.5
The net income has contracted by 20% YoY
Royalty Pharma plc - Class A's EPS has decreased by 19% YoY and by 2.1% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: ANIP ABT LLY

Key stats

What are the main financial stats of RPRX

RPRX stock price

How has the Royalty Pharma plc - Class A stock price performed over time
Intraday
1.21%
1 week
4.62%
1 month
4.95%
1 year
68.85%
YTD
58.67%
QTD
9.35%

Financial performance

How have Royalty Pharma plc - Class A's revenue and profit performed over time
Revenue
$2.54B
Gross profit
$2.54B
Operating income
$1.51B
Net income
$815M
Gross margin
100%
Net margin
32.1%
Royalty Pharma plc - Class A's net margin has decreased by 28% YoY and by 6% QoQ
The operating margin has declined by 25% year-on-year and by 8% since the previous quarter
The net income has contracted by 20% YoY
The operating income has contracted by 18% YoY and by 4.8% from the previous quarter

Price vs fundamentals

How does RPRX's price correlate with its fundamentals

Growth

What is Royalty Pharma plc - Class A's growth rate over time

Valuation

What is Royalty Pharma plc - Class A stock price valuation
RPRX P/E details
P/E
32.61
P/B
3.61
P/S
10.76
EV/EBIT
36.91
EV/EBITDA
36.91
EV/Sales
17.11
The P/E is 35% higher than the last 4 quarters average of 24.1 but 28% lower than the 5-year quarterly average of 45.5
Royalty Pharma plc - Class A's EPS has decreased by 19% YoY and by 2.1% QoQ
RPRX's P/B is 72% above its 5-year quarterly average of 2.1 and 39% above its last 4 quarters average of 2.6
RPRX's equity is up by 3% year-on-year
The P/S is 61% above the 5-year quarterly average of 6.7 and 35% above the last 4 quarters average of 8.0
The revenue has increased by 10% YoY and by 3.9% from the previous quarter

Efficiency

How efficient is Royalty Pharma plc - Class A business performance
The ROA has decreased by 28% YoY and by 4.7% from the previous quarter
RPRX's ROE is down by 19% YoY and by 3.5% from the previous quarter
The ROIC is down by 18% YoY
Royalty Pharma plc - Class A's return on sales has decreased by 17% YoY and by 2.9% QoQ

Dividends

What is RPRX's dividend history
Dividend details
DPS
$0.93
Dividend yield
1.51%
Payout ratio
49.2%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Royalty Pharma plc - Class A financials performed over time
Royalty Pharma plc - Class A's total assets is 98% more than its total liabilities
The current ratio has surged by 122% year-on-year and by 5% since the previous quarter
The company's quick ratio has surged by 121% YoY and by 6% QoQ
Royalty Pharma plc - Class A's debt is 8% lower than its equity
Royalty Pharma plc - Class A's debt has increased by 12% YoY
The debt to equity has increased by 10% YoY and by 2.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.